ARF1 regulates the Rho/MLC pathway to control EGF-dependent breast cancer cell invasion

Molecular Biology of the Cell

Volumn 25, Issue 1, 2014, Pages 17-29

  Schlienger, Sabrina ^a   Campbell, Shirley ^a   Claing, Audrey ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 1; GELATINASE B; MYOSIN LIGHT CHAIN; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE;

ANIMAL CELL; ARTICLE; BASEMENT MEMBRANE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL INVASION; CELL LYSATE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; MIXED LYMPHOCYTE CULTURE; MODULATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR INVASION; ZYMOGRAPHY;

ADP-RIBOSYLATION FACTOR 1; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURFACE EXTENSIONS; CELL-DERIVED MICROPARTICLES; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 9; MYOSIN LIGHT CHAINS; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84891759055     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E13-06-0335     Document Type: Article

References (57)

1. Alexander NR, Branch KM, Parekh A, Clark ES, Iwueke IC, Guelcher SA, Weaver AM (2008). Extracellular matrix rigidity promotes invadopodia activity. Curr Biol 18, 1295-1299.
2. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K (1996). Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271, 20246-20249.
3. Bendayan M (1995). Colloidal gold post-embedding immunocytochemistry. Prog Histochem Cytochem 29, 1-159.
4. Boulay PL, Cotton M, Melancon P, Claing A (2008). ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells. J Biol Chem 283, 36425-36434.
5. Boulay PL, Schlienger S, Lewis-Saravalli S, Vitale N, Ferbeyre G, Claing A (2011). ARF1 controls proliferation of breast cancer cells by regulating the retinoblastoma protein. Oncogene 30, 3846-3861.
6. Bravo-Cordero JJ, Oser M, Chen X, Eddy R, Hodgson L, Condeelis J (2011). A novel spatiotemporal RhoC activation pathway locally regulates cofilin activity at invadopodia. Curr Biol 21, 635-644.
7. Brown PD (1995). Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 35, 293-301.
8. Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van Obberghen E, Tartare-Deckert S (2003). Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 278, 11888-11896.
9. Clark EA, Golub TR, Lander ES, Hynes RO (2000). Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532-535.
10. Cocucci E, Racchetti G, Meldolesi J (2009). Shedding microvesicles: artefacts no more. Trends Cell Biol 19, 43-51.
11. Cohen LA, Honda A, Varnai P, Brown FD, Balla T, Donaldson JG (2007). Active Arf6 recruits ARNO/cytohesin GEFs to the PM by binding their PH domains. Mol Biol Cell 18, 2244-2253.
12. Cotton M, Boulay PL, Houndolo T, Vitale N, Pitcher JA, Claing A (2007). Endogenous ARF6 interacts with Rac1 upon angiotensin II stimulation to regulate membrane ruffling and cell migration. Mol Biol Cell 18, 501-511.
13. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS (2002). The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111, 29-40.
14. Dolo V, D'Ascenzo S, Violini S, Pompucci L, Festuccia C, Ginestra A, Vittorelli ML, Canevari S, Pavan A (1999). Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 17, 131-140.
15. D'Souza-Schorey C, Chavrier P (2006). ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol 7, 347-358.
16. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B (2002). Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87, 635-644.
17. Gilcrease MZ, Zhou X, Lu X, Woodward WA, Hall BE, Morrissey PJ (2009). Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. J Exp Clin Cancer Res 28, 67.
18. Hashimoto S, Onodera Y, Hashimoto A, Tanaka M, Hamaguchi M, Yamada A, Sabe H (2004). Requirement for Arf6 in breast cancer invasive activities. Proc Natl Acad Sci USA 101, 6647-6652.
19. Hegedus L, Cho H, Xie X, Eliceiri GL (2008). Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J Cell Physiol 216, 480-485.
20. Ho WT, Exton JH, Williger BT (2003). Arfaptin 1 inhibits ADP-ribosylation factor-dependent matrix metalloproteinase-9 secretion induced by phorbol ester in HT 1080 fibrosarcoma cells. FEBS Lett 537, 91-95.
21. Huveneers S, Danen EH (2009). Adhesion signaling-crosstalk between integrins, Src and Rho. J Cell Sci 122, 1059-1069.
22. Kakinuma N, Roy BC, Zhu Y, Wang Y, Kiyama R (2008). Kank regulates RhoA-dependent formation of actin stress fibers and cell migration via 14-3-3 in PI3K-Akt signaling. J Cell Biol 181, 537-549.
23. Karnoub AE, Weinberg RA (2008). Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9, 517-531.
24. Kelly T, Yan Y, Osborne RL, Athota AB, Rozypal TL, Colclasure JC, Chu WS (1998). Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin Exp Metastasis 16, 501-512.
25. Kimura K et al. (1996). Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273, 245-248.
26. Lee GY, Kenny PA, Lee EH, Bissell MJ (2007). Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4, 359-365.
27. Lewis-Saravalli S, Campbell S, Claing A (2013). ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells. Cell Signal 25, 1813-1819.
28. Li B, Antonyak MA, Zhang J, Cerione RA (2012). RhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells. Oncogene 31, 4740-4749.
29. Li L, Chen P, Ling Y, Song X, Lu Z, He Q, Li Z, Lu N, Guo Q (2011). Inhibitory effects of GL-V9 on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-2/9. Eur J Pharm Sci 43, 393-399.
30. Mardilovich K, Olson MF, Baugh M (2012). Targeting Rho GTPase signaling for cancer therapy. Future Oncol 8, 165-177.
31. Molli PR, Adam L, Kumar R (2008). Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPase. Clin Cancer Res 14, 6161-6170.
32. Monsky WL, Lin CY, Aoyama A, Kelly T, Akiyama SK, Mueller SC, Chen WT (1994). A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res 54, 5702-5710.
33. Muralidharan-Chari V, Clancy J, Plou C, Romao M, Chavrier P, Raposo G, D'Souza-Schorey C (2009). ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol 19, 1875-1885.
34. Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C (2010). Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci 123, 1603-1611.
35. Murphy DA, Courtneidge SA (2011). The "ins" and "outs" of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol 12, 413-426.
36. Nakahara H, Howard L, Thompson EW, Sato H, Seiki M, Yeh Y, Chen WT (1997). Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci USA 94, 7959-7964.
37. Norman JC, Jones D, Barry ST, Holt MR, Cockcroft S, Critchley DR (1998). ARF1 mediates paxillin recruitment to focal adhesions and potentiates Rho-stimulated stress fiber formation in intact and permeabilized Swiss 3T3 fibroblasts. J Cell Biol 143, 1981-1995.
38. Piekny AJ, Glotzer M (2008). Anillin is a scaffold protein that links RhoA, actin, and myosin during cytokinesis. Curr Biol 18, 30-36.
39. Pille JY et al. (2005). Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 11, 267-274.
40. Qiang YW, Yao L, Tosato G, Rudikoff S (2004). Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood 103, 301-308.
41. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ (2006). Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 20, 1487-1495.
42. Ruth MC, Xu Y, Maxwell IH, Ahn NG, Norris DA, Shellman YG (2006). RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. J Invest Dermatol 126, 862-868.
43. Sabe H, Hashimoto S, Morishige M, Ogawa E, Hashimoto A, Nam JM, Miura K, Yano H, Onodera Y (2009). The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis. Traffic 10, 982-993.
44. Sahai E, Marshall CJ (2002). RHO-GTPases and cancer. Nat Rev Cancer 2, 133-142.
45. Sakurai-Yageta M, Recchi C, Le Dez G, Sibarita JB, Daviet L, Camonis J, D'Souza-Schorey C, Chavrier P (2008). The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA. J Cell Biol 181, 985-998.
46. Seals DF, Azucena EF Jr, Pass I, Tesfay L, Gordon R, Woodrow M, Resau JH, Courtneidge SA (2005). The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell 7, 155-165.
47. Simpson KJ, Dugan AS, Mercurio AM (2004). Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res 64, 8694-8701.
48. Stylli SS, Stacey TT, Verhagen AM, Xu SS, Pass I, Courtneidge SA, Lock P (2009). Nck adaptor proteins link Tks5 to invadopodia actin regulation and ECM degradation. J Cell Sci 122, 2727-2740.
49. Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S, Hiai H, Fukumoto M (1998). Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77, 147-152.
50. Tague SE, Muralidharan V, D'Souza-Schorey C (2004). ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc Natl Acad Sci USA 101, 9671-9676.
51. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V (2002). Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 160, 673-680.
52. Vigil D, Cherfils J, Rossman KL, Der CJ (2010). Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy. Nat Rev Cancer 10, 842-857.
53. Weaver AM (2006). Invadopodia: specialized cell structures for cancer invasion. Clin Exp Metastasis 23, 97-105.
54. Welch HC, Coadwell WJ, Stephens LR, Hawkins PT (2003). Phosphoinositide 3-kinase-dependent activation of Rac. FEBS Lett 546, 93-97.
55. Wheeler AP, Ridley AJ (2004). Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res 301, 43-49.
56. Wu M, Wu ZF, Rosenthal DT, Rhee EM, Merajver SD (2010). Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers. Cancer 116, 2768-2782.
57. Yonemura S, Hirao-Minakuchi K, Nishimura Y (2004). Rho localization in cells and tissues. Exp Cell Res 295, 300-314.